Halozyme (Global Alliance Management)
Renee Tannenbaum is Vice President of Global Alliance Management at Halozyme. In this role, she leads a team of Alliance and Program Leaders who manage the 9 partnerships and more than 15 programs with biopharmaceutical companies for the ENHANZE drug delivery technology.
Renee has more than 25 years of operating and general management experience with roles in research and development, medical affairs, sales and marketing and managed care. Prior to joining Halozyme, she held several executive level positions, including Head of Global Customer Excellence, AbbVie; Executive Vice President and Chief Commercial Officer, Élan Pharmaceuticals, Inc.; Head, Global Commercial Operations, Novartis AG; and Vice President, ConvaTec Americas, Bristol-Myers Squibb Corporation.
In addition to her role at Halozyme, Renee serves on the Board of Directors of Zogenix, Inc. a biopharmaceutical company that specializes in the development of CNS therapies, with a focus on rare epilepsies. She is active in a number of organizations including Women Business Leaders in the Healthcare Industry (WBL), and the Healthcare Business Women’s Association.
Renee earned her Bachelor of Science degree at the University of Connecticut, School of Pharmacy, her Doctor of Pharmacy degree at the Philadelphia College of Pharmacy and Sciences and her MBA from Temple University School of Business in Philadelphia. She completed a residency in Hospital Pharmacy at Thomas Jefferson University Hospital. She currently serves as Adjunct Professor at the University of the Sciences at Philadelphia.